Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, Cheung P, Szumacher E, Liu S, Chu W, Zhang L, Mamedov A, Loblaw A. Morton G, et al. Among authors: cheung p. Radiother Oncol. 2020 May;146:90-96. doi: 10.1016/j.radonc.2020.02.009. Epub 2020 Mar 5. Radiother Oncol. 2020. PMID: 32146259 Clinical Trial.
Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy.
Pearce A, Choo R, Danjoux C, Morton G, Loblaw DA, Szumacher E, Cheung P, Deboer G, Chander S. Pearce A, et al. Among authors: cheung p. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):78-83. doi: 10.1016/j.ijrobp.2005.11.041. Epub 2006 Mar 24. Int J Radiat Oncol Biol Phys. 2006. PMID: 16563657 Clinical Trial.
Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy.
Choo R, Pearce A, Danjoux C, Morton G, Deboer G, Szumacher E, Loblaw A, Cheung P. Choo R, et al. Among authors: cheung p. Eur Urol. 2007 Dec;52(6):1645-50. doi: 10.1016/j.eururo.2006.11.018. Epub 2006 Nov 15. Eur Urol. 2007. PMID: 17140722
Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G. Lim TS, et al. Among authors: cheung pc. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):85-92. doi: 10.1016/j.ijrobp.2007.12.041. Epub 2008 Mar 20. Int J Radiat Oncol Biol Phys. 2008. PMID: 18355982 Clinical Trial.
Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.
Choo R, Pearse M, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P. Choo R, et al. Among authors: cheung p. Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):989-95. doi: 10.1016/j.ijrobp.2008.02.044. Epub 2008 Apr 23. Int J Radiat Oncol Biol Phys. 2008. PMID: 18436391 Clinical Trial.
1,634 results